Progressive keratoconus remains a leading cause of preventable visual impairment in young populations worldwide. Clinicians often rely on corneal crosslinking long-term outcomes to guide treatment decisions and set patient expectations. Recent evidence from a diverse five-year study confirms that epithelium-off corneal crosslinking (CXL) provides robust, sustained improvements in both visual function and corneal structure across all age groups.

The research analyzed 243 eyes from pediatric, adolescent, and adult patients. Notably, corrected distance visual acuity (CDVA) showed significant improvement from baseline. This visual gain remained stable throughout the 60-month follow-up period. Furthermore, maximum keratometry (Kmax) values demonstrated significant flattening within the first year. These structural benefits persisted for the duration of the study, indicating that the procedure effectively halts the progression of ectasia.

Evaluating Corneal Crosslinking Long-Term Outcomes

One of the most critical findings involves the efficacy of CXL in pediatric patients. Although younger patients often present with more aggressive disease, they achieved stability comparable to the adult cohort. Specifically, Kmax improved by a mean of 1.2 diopters at 12 months. In addition, minimum central corneal thickness (CCTmin) and wavefront aberrations showed favorable stabilization. Consequently, early intervention in younger populations is highly recommended to preserve long-term visual potential.

Safety data from the study were equally encouraging. The incidence of serious complications, such as infectious keratitis or persistent scarring, was less than 2%. Most patients experienced only transient corneal haze, which typically resolved within the first postoperative year. Therefore, epithelium-off CXL remains a highly effective and safe gold standard for managing progressive keratoconus across a diverse patient demographic.

Frequently Asked Questions

Is corneal crosslinking effective for pediatric patients over the long term?

Yes, long-term data indicates that pediatric patients achieve significant and sustained stabilization of keratoconus similar to adults, with Kmax values remaining stable for five years or more.

Can patients expect visual improvement after CXL?

While the primary goal of CXL is to halt progression, many patients experience a significant improvement in corrected distance visual acuity (CDVA) that persists for several years post-procedure.

What are the common risks associated with the epithelium-off procedure?

Common risks include transient corneal haze and minor discomfort during the initial healing phase. Serious complications like infection or permanent scarring are rare, occurring in fewer than 2% of cases.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Chen KM et al. Long-Term Outcomes of Corneal Crosslinking for Keratoconus Across Pediatric, Adolescent, and Adult Populations in a Diverse U.S. Population. J Cataract Refract Surg. 2026 Mar 03. doi: 10.1097/j.jcrs.0000000000001932. PMID: 41774470.

Cortina MS et al. Safety and Efficacy of Epithelium-Off Corneal Collagen Cross-Linking for the Treatment of Corneal Ectasia. Ophthalmology. 2024 Oct;131(10):1234-1242.

Wollensak G et al. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. American Journal of Ophthalmology. 2003;135(5):620-627.